undamentalytics Newsletter
Sign in

Amphastar Pharmaceuticals, Inc. revenue

Amphastar Pharmaceuticals, Inc.'s revenue was $720m in fiscal 2025, down 1.7% on the year before. Since fiscal 2012 ($204m) it has grown at a compound 10.2% a year. Over the last twelve months it was $730m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue204230210252255240295322350438499644732720730
Growth on the year before—+12.4%−8.4%+19.5%+1.4%−5.9%+22.7%+9.4%+8.5%+25.1%+14.0%+29.1%+13.6%−1.7%—
Gross profit9087517710491107132143200249351374356348
Gross margin44.2%37.9%24.4%30.8%40.8%37.7%36.3%40.9%41.0%45.6%49.9%54.5%51.1%49.5%47.7%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Geography
Region Revenue Share YoY
United States $681M 94.7% ▼ 3.7%
France $35.3M 4.9% ▲ 76.9%
China $3.2M 0.4% ▼ 26.6%

From Amphastar Pharmaceuticals, Inc.'s 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Amphastar Pharmaceuticals, Inc. $730m 1.0% 10.5%
Pacira Biosciences, Inc. $746m 5.7% 3.7%
Travere Therapeutics, Inc. $651m 49.4% 71.3%
Emergent Biosolutions Inc. $649m -17.7% -16.2%
Corcept Therapeutics Inc $831m 16.0% 24.7%
Supernus Pharmaceuticals, Inc. $865m 26.9% 12.3%

Compare with peers

Head to head: AMPH vs PCRXAMPH vs TVTXAMPH vs EBS

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Amphastar Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Amphastar Pharmaceuticals, Inc.